CN Patent

CN114641276A — 包含glp-1激动剂、sglt2抑制剂和n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐的固体组合物

Assigned to Novo Nordisk AS · Expires 2022-06-17 · 4y expired

What this patent protects

本发明涉及包含GLP‑1激动剂、SGLT2抑制剂、N‑(8‑(2‑羟基苯甲酰基)氨基)辛酸的盐和水溶助长剂的药物组合物。本发明进一步涉及这类组合物的制备方法，及其在医学中的用途。

USPTO Abstract

本发明涉及包含GLP‑1激动剂、SGLT2抑制剂、N‑(8‑(2‑羟基苯甲酰基)氨基)辛酸的盐和水溶助长剂的药物组合物。本发明进一步涉及这类组合物的制备方法，及其在医学中的用途。

Drugs covered by this patent

Patent Metadata

Patent number
CN114641276A
Jurisdiction
CN
Classification
—
Expires
2022-06-17
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.